Dilsizian V, Bonow R O, Epstein S E, Fananapazir L
Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Am Coll Cardiol. 1993 Sep;22(3):796-804. doi: 10.1016/0735-1097(93)90193-5.
The purpose of this study was to determine the frequency of myocardial ischemia as a potential mechanism for cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy who experienced such complications.
Sudden cardiac death and syncope occur frequently in patients with hypertrophic cardiomyopathy. Although ventricular arrhythmias account for most of these events in adult patients, the mechanism responsible for cardiac arrest and syncope in young patients has not been established.
Twenty-three patients with hypertrophic cardiomyopathy, aged 6 to 23 years, with previous cardiac arrest (n = 8), syncope (n = 7) or a family history of sudden cardiac death (n = 8) were evaluated to determine the prevalence of spontaneous ambulatory ventricular tachycardia (24- to 72-h electrocardiographic [ECG] monitoring), exercise-induced myocardial ischemia (thallium scintigraphy) and inducibility of ventricular tachycardia (electrophysiologic studies).
Three of 15 patients with a history of cardiac arrest or syncope had ventricular tachycardia on ambulatory ECG monitoring. However, all 15 patients, had inducible ischemia by thallium scintigraphy compared with only 3 (37%) of 8 patients with no such history (p < 0.01). In contrast, ventricular tachycardia induction was uncommon in all of the young patients (27% in those with cardiac arrest or syncope; 0% in the others). During therapy for ischemia with verapamil alone or in combination with beta-adrenergic blocking agents, only 4 of the 15 patients with cardiac arrest or syncope had further episodes. In three of the four patients, these events were temporally related to discontinuation of verapamil. Among eight patients who had a repeat exercise thallium study while receiving anti-ischemic therapy, seven (88%) had improved regional thallium uptake, of whom three had normal thallium studies.
These data suggest that in young patients with hypertrophic cardiomyopathy, sudden cardiac arrest or syncope is frequently related to ischemia rather than to a primary arrhythmogenic ventricular substrate.
本研究旨在确定心肌缺血作为肥厚型心肌病年轻患者心脏骤停和晕厥潜在机制的发生频率,这些患者曾经历过此类并发症。
肥厚型心肌病患者中猝死和晕厥频繁发生。虽然室性心律失常是成年患者这些事件的主要原因,但年轻患者心脏骤停和晕厥的机制尚未明确。
对23例年龄在6至23岁的肥厚型心肌病患者进行评估,这些患者既往有心脏骤停(n = 8)、晕厥(n = 7)或心源性猝死家族史(n = 8),以确定动态心电图监测下自发室性心动过速的发生率(24至72小时心电图[ECG]监测)、运动诱发的心肌缺血(铊闪烁显像)以及室性心动过速的诱发率(电生理研究)。
15例有心脏骤停或晕厥病史的患者中,3例在动态心电图监测时有室性心动过速。然而,所有15例患者通过铊闪烁显像均显示有可诱导的缺血,相比之下,8例无此类病史的患者中只有3例(37%)有可诱导的缺血(p < 0.01)。相反,所有年轻患者中室性心动过速的诱发并不常见(有心脏骤停或晕厥的患者中为27%;其他患者中为0%)。在单独使用维拉帕米或联合β-肾上腺素能阻滞剂进行缺血治疗期间,15例有心脏骤停或晕厥的患者中只有4例出现进一步发作。在这4例患者中的3例中,这些事件在时间上与维拉帕米停药有关。在接受抗缺血治疗时进行重复运动铊研究的8例患者中,7例(88%)局部铊摄取改善,其中3例铊研究结果正常。
这些数据表明,在肥厚型心肌病年轻患者中,心脏骤停或晕厥通常与缺血有关,而非与原发性致心律失常性心室基质有关。